David Amsellem
Stock Analyst at Piper Sandler
(4.71)
# 125
Out of 5,169 analysts
166
Total ratings
61.48%
Success rate
21.84%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $219 → $232 | $180.26 | +28.70% | 16 | Mar 19, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $40 → $41 | $29.19 | +40.46% | 12 | Mar 4, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $22.25 | +115.73% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $58.47 | +28.27% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $348.83 | +23.84% | 7 | Feb 18, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $206.36 | +44.89% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $182.44 | -2.98% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $13.52 | -11.24% | 8 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $157.39 | +41.69% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $7.46 | +141.29% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.53 | +255.73% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.05 | +97.78% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $5.53 | +44.67% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $12.30 | +5.69% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $128.78 | +39.00% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $27.45 | +63.93% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $49.03 | +32.57% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $19.43 | +28.67% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $33.72 | +258.84% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.22 | +189.39% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $36.19 | +2.24% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $74.48 | -8.69% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.00 | -40.00% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.58 | +86.01% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.10 | +578.51% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $27.67 | +51.79% | 3 | Oct 16, 2023 |
Jazz Pharmaceuticals
Mar 19, 2026
Maintains: Overweight
Price Target: $219 → $232
Current: $180.26
Upside: +28.70%
Teva Pharmaceutical Industries
Mar 4, 2026
Reiterates: Overweight
Price Target: $40 → $41
Current: $29.19
Upside: +40.46%
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $22.25
Upside: +115.73%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $58.47
Upside: +28.27%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $348.83
Upside: +23.84%
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $206.36
Upside: +44.89%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $182.44
Upside: -2.98%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $13.52
Upside: -11.24%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $157.39
Upside: +41.69%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $7.46
Upside: +141.29%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $2.53
Upside: +255.73%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.05
Upside: +97.78%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $5.53
Upside: +44.67%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.30
Upside: +5.69%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $128.78
Upside: +39.00%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $27.45
Upside: +63.93%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $49.03
Upside: +32.57%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $19.43
Upside: +28.67%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $33.72
Upside: +258.84%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.22
Upside: +189.39%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $36.19
Upside: +2.24%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $74.48
Upside: -8.69%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.00
Upside: -40.00%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.58
Upside: +86.01%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.10
Upside: +578.51%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $27.67
Upside: +51.79%